Dementia, Gait Disorders and Urinary Incontinence: Normal Pressure Hydrocephalus vs Other Causes

Most readers benefit from the Quick Summary plus the sections on Normal Pressure Hydrocephalus, Integrated Diagnostic Evaluation, and Temporary CSF Reduction (Tap Test). Other sections provide deeper clinical context.

A Real-World Clinical Scenario

An 85-year-old woman gradually develops difficulty walking, frequent falls, loss of bladder control, and progressive cognitive decline with episodes of agitation and confusion. Over time, she is prescribed antidepressants and sedative medications, which further worsen gait instability and alertness.

Brain MRI shows generalized cerebral atrophy with ischemic white-matter changes, enlarged ventricles, and features suggestive of hydrocephalus. It remains unclear whether her symptoms are driven primarily by neurodegenerative disease, vascular brain injury, hydrocephalus, or a combination of all three.

The central question becomes: is hydrocephalus a meaningful contributor to her symptoms, and if so, is there a realistic chance that surgical intervention (VP shunt) could help?

Particularly in developed countries, with their growing elderly populations, these cases are becoming increasingly common. The most important question is not whether the ventricles are enlarged, but whether the symptoms are truly caused by NPH — because only then surgery can lead to meaningful improvement.

Brain Atrophy, Vascular Changes, and Dementia

Age-related brain atrophy and small vessel disease are common findings in older adults and are often part of the normal aging process. Brain MRI may show widened cortical sulci, reduced overall brain volume, and small ischemic lesions within the white matter. These findings reflect chronic degenerative changes of small cerebral blood vessels rather than an active or rapidly progressive disease. Over time, such microvascular changes—often related to hyaline-type degeneration of small arteries—can impair blood flow to deep brain structures and contribute to cognitive slowing and gait instability. Importantly, these age-related changes may coexist with hydrocephalus and partially overlap with its symptoms, which is why they should be interpreted as background findings unless clinical features and CSF dynamics suggest otherwise.

These processes alone can explain:

• slow cognitive decline,
• impaired executive function (difficulty planning, organizing, and managing everyday tasks)
• gait slowing,
• urinary urgency or incontinence.

Importantly, atrophy-related and vascular dementia are not reversible.
When they represent the dominant process, surgical treatment aimed at cerebrospinal fluid (CSF) diversion is unlikely to produce meaningful benefit. Read more about brain anatomy on this page.

Alzheimer’s Disease and Other Neurodegenerative Dementias

Alzheimer’s disease and other neurodegenerative dementias represent a fundamentally different disease process from hydrocephalus. They are characterized by progressive neuronal loss, synaptic degeneration, and accumulation of abnormal proteins within the brain, leading to irreversible cognitive decline.

In Alzheimer’s disease, MRI typically shows predominant hippocampal and medial temporal lobe atrophy rather than ventricular enlargement out of proportion to cortical atrophy. Gait and urinary symptoms usually appear late in the disease course and are secondary to advanced cognitive impairment rather than a primary neurological mechanism.

Other degenerative dementias—such as dementia with Lewy bodies, frontotemporal dementia, or Parkinson-related dementia—have distinct clinical patterns and imaging features and do not improve with cerebrospinal fluid diversion procedures.

Importantly, neurodegenerative dementias may coexist with vascular changes or hydrocephalus in older patients, creating diagnostic overlap. However, their presence significantly reduces the likelihood of meaningful improvement after shunt surgery and must be carefully considered before any invasive intervention.

Normal Pressure Hydrocephalus (NPH)

Normal pressure hydrocephalus is a chronic disorder of cerebrospinal fluid (CSF) circulation characterized by progressive enlargement of the brain ventricles without sustained elevation of intracranial pressure on routine measurement. It primarily affects older adults and develops slowly over months to years.

How NPH Develops and Damages the Brain

In NPH, cerebrospinal fluid is produced normally but is inadequately absorbed, leading to gradual ventricular expansion. Because this process evolves slowly, the brain adapts to the increasing ventricular size without triggering the acute warning signs typically associated with raised intracranial pressure, such as severe headache, vomiting, or visual disturbances.

Despite “normal” measured pressure, ventricular enlargement exerts chronic mechanical stress on surrounding brain tissue. The expanding ventricles stretch and compress the periventricular white matter, disrupt long neural pathways, and impair microcirculation. This results in reduced signal transmission between deep brain structures and the frontal lobes, particularly affecting motor planning, executive function, and bladder control.

Importantly, the absence of sustained pressure elevation does not mean absence of brain injury. In NPH, damage occurs through long-term distortion and shear stress, combined with impaired clearance of interstitial fluid around the ventricles.

Image: In NPH, there is a gradual and slow enlargement of the ventricles due to the inadequate resorption of CSF, which is constantly being produced. Thanks to intracranial adaptive mechanisms, there is no increase in ICP. However, the accumulation of CSF leads to brain tissue damage due to the stretching of the ventricular walls and the penetration of CSF into the periventricular areas. Read more about the anatomy of the ventricles on this page.

Why Intracranial Pressure Is Often Normal

In normal pressure hydrocephalus, excess cerebrospinal fluid builds up slowly over time. Because this process is gradual, the brain has time to adapt instead of reacting with a sudden rise in pressure. As part of this adaptation, the brain makes room for the expanding ventricles by gradually redistributing fluids within the skull. As a result, the fluid-filled spaces in the brain can enlarge without causing persistently high intracranial pressure, and routine lumbar puncture measurements often appear normal. Even so, abnormal fluid accumulation continues, and the gradual stretching of surrounding brain tissue can still lead to progressive neurological symptoms, such as difficulty walking and memory loss.

In clinical practice, the term normal pressure hydrocephalus is often used as a broad descriptive label. From a diagnostic and therapeutic perspective, however, the majority of older patients evaluated for this condition fall within the category of idiopathic normal pressure hydrocephalus (iNPH), which develops gradually without a clearly identifiable precipitating event such as acute subarachnoid hemorrhage, meningitis, traumatic brain injury, or prior neurosurgical intervention. Secondary forms of NPH may occur after such insults to cerebrospinal fluid absorption pathways, but in elderly patients the distinction between idiopathic and secondary NPH is frequently blurred, particularly when potential causative events occurred many years earlier. For this reason, real-world clinical decision-making relies primarily on the clinical presentation, imaging characteristics, and response to cerebrospinal fluid drainage tests, rather than on strict etiological classification alone.

Clinical Manifestations

The characteristic clinical picture of NPH reflects the specific brain regions affected by ventricular enlargement:

• Gait disturbance is usually the earliest and most prominent symptom. Patients develop a broad-based, short-stepped, shuffling gait with difficulty initiating movement and turning.
• Cognitive impairment typically follows and reflects frontal–subcortical dysfunction, with slowed thinking, impaired attention, reduced executive function, and apathy rather than primary memory loss.
• Urinary dysfunction appears later and ranges from urgency and frequency to loss of bladder control.

This symptom combination—gait disturbance, cognitive decline, and urinary dysfunction—forms the classic clinical triad of NPH, although not all patients present with all three features simultaneously.

A diagnostic challenge arises when NPH (Normal Pressure Hydrocephalus) or communicating hydrocephalus occurs alongside conditions that can themselves cause hydrocephalus, such as Chiari malformation.

Communicating Chronic Hydrocephalus

Communicating hydrocephalus refers to a broader category in which cerebrospinal fluid circulates freely through the ventricular system but is inadequately absorbed. Reduced CSF absorption may develop secondary to identifiable conditions, such as prior subarachnoid hemorrhage, meningitis or other central nervous system infections, inflammatory processes, previous neurosurgical procedures, or diffuse leptomeningeal disease. In these situations, scarring, fibrosis, or obstruction of resorptive surfaces interferes with normal CSF outflow.

In other patients, particularly older adults, no single triggering event is identified. Instead, impaired absorption appears to result from gradual age-related degeneration of the CSF resorption system, including reduced efficiency of arachnoid granulations and altered venous compliance. This slow degenerative process may progress over years, leading to ventricular enlargement without an acute rise in intracranial pressure.

Because both mechanisms can produce similar imaging and clinical features, communicating hydrocephalus represents a heterogeneous group rather than a single disease entity.

In contrast to NPH, communicating hydrocephalus may be associated with:

• persistently elevated intracranial pressure,
• pressure-related symptoms such as headache,
• earlier clinical recognition.

However, communicating hydrocephalus can also evolve slowly, particularly when pressure elevation is mild or fluctuating. In such cases, patients may experience long-term gait impairment and cognitive decline over years.

Normal pressure hydrocephalus and other forms of chronic communicating hydrocephalus are most likely caused by impaired cerebrospinal fluid (CSF) resorption. CSF is continuously produced and absorbed, with the entire CSF volume being renewed several times per day. When CSF resorption is significantly reduced, ventricular enlargement is typically accompanied by an increase in intracranial pressure, as seen in communicating hydrocephalus with elevated pressure. When the reduction in resorption is more gradual or less severe, compensatory intracranial mechanisms may be sufficient to maintain intracranial pressure within the normal range, as in normal pressure hydrocephalus (NPH). In this setting, brain ventricles progressively enlarge despite normal measured pressure, and chronic mechanical stress with periventricular tissue injury develops over time. As a result, neurological damage may occur even in the absence of sustained intracranial pressure elevation.

Overlap Between Normal Pressure Hydrocephalus and Degenerative Dementias (Atrophic, Alzheimer’s, and Others)

Neuropathological, imaging, and biomarker studies show that normal pressure hydrocephalus frequently coexists with other degenerative brain processes, most commonly age-related cerebral atrophy and neurodegenerative dementias, rather than representing an isolated disease entity.

Reported rates of combined pathology vary depending on diagnostic methods and patient selection:

• Degenerative or atrophic brain changes are present in the majority of older patients diagnosed with NPH,
• Alzheimer-type pathology is identified in approximately 20–40% of patients undergoing shunt surgery,
• higher rates are reported when CSF biomarkers, amyloid PET, or postmortem analysis are used.

This overlap explains several well-known clinical observations regarding shunt treatment:

• Gait disturbance improves more reliably than cognition after shunt treatment,
• Cognitive improvement is often partial, delayed, or absent, particularly when significant cortical atrophy is present,
• Treatment outcomes are inherently probabilistic, reflecting the combined contribution of hydrocephalus-related and degenerative brain injury.

Importantly, the presence of atrophic or degenerative dementia does not automatically exclude a contribution from hydrocephalus, but it significantly influences the magnitude, durability, and domains of potential improvement.

Clinical and Neurological Assessment of Normal Pressure Hydrocephalus (NPH)

The clinical evaluation aims to create a clear picture of how cerebrospinal fluid buildup affects daily function. Assessment focuses on four key domains:

1. Walking and Balance (Gait)
Walking is carefully observed, including how movement is initiated, step length, walking speed, and turning. A typical finding in NPH is a wide-based gait or the sensation that the feet are “stuck” to the floor. Balance and postural stability are also assessed to estimate the risk of falls.

2. Physical Movement and Strength
Muscle tone, movement speed, coordination, and reflexes are examined. Particular attention is paid to whether abnormalities are symmetric, which helps distinguish NPH from conditions such as stroke or Parkinson’s disease.

3. Cognitive Function and Mental Processing Speed
Cognitive changes in NPH are often characterized by mental slowing rather than prominent memory loss. Testing focuses on attention, processing speed, planning, and the ability to manage multiple tasks. This pattern differs from typical neurodegenerative dementias (such as Alzheimer’s disease), as NPH primarily affects frontal–subcortical networks rather than memory storage systems.

4. Bladder Control
Urinary symptoms are evaluated, ranging from increased urgency and frequency to loss of bladder control in more advanced stages.

Severity of Clinical Involvement in Normal Pressure Hydrocephalus

Different centers use different grading scales; the goal is to document baseline function consistently.

Why Formal Testing Is Used (MMSE, MoCA, Timed Tasks)
Formal cognitive and gait tests complement the neurological examination by providing standardized, repeatable measurements. Together, the clinical findings and test results establish a functional baseline for monitoring disease progression and for meaningful comparison before and after diagnostic procedures (such as a lumbar tap test) or surgical treatment (shunt placement), helping determine whether intervention has produced true clinical improvement.

Integrated Diagnostic Evaluation

No single test can determine whether hydrocephalus is clinically relevant. Accurate assessment requires integrated interpretation of multiple factors, including:

• brain imaging findings,
• medical history and coexisting illnesses,
• medication effects, particularly sedatives and psychoactive drugs,
• clinical response to trial medications that reduce cerebrospinal fluid (CSF) production,
• laboratory studies to exclude metabolic contributors,
• eye examination to assess for findings that may suggest increased intracranial pressure,
• prior neurological events such as trauma or intracranial bleeding,
• In selected cases, cerebrospinal fluid biomarkers may be helpful to clarify diagnostic overlap with neurodegenerative diseases, particularly Alzheimer’s disease. These tests are not performed routinely in all patients with suspected iNPH but may be considered when cognitive impairment is prominent or atypical; typical examples include amyloid beta (Aβ42), tau proteins, and neurofilament light chain, which can support differential diagnosis and help estimate the likelihood of benefit from shunt surgery..

No individual factor is sufficient on its own. Rather, the interaction between clinical findings, imaging features, cognitive profile, eye examination, medication adjustments, response to trial therapies, and the tempo of symptom progression determines whether hydrocephalus is likely contributing meaningfully to a patient’s condition.

Accurately integrating these elements requires substantial clinical experience, particularly when determining whether a patient’s symptoms are driven primarily by potentially reversible hydrocephalus-related dysfunction or by coexisting degenerative or vascular brain disease, both of which can present with ventricular enlargement. In practice, this level of judgment typically requires a neurologist or neurosurgeon familiar with the full spectrum of hydrocephalus presentations.

When symptoms and imaging suggest a potentially reversible component, cautious further evaluation—such as lumbar puncture—may be appropriate. When degenerative disease clearly predominates, aggressive intervention is unlikely to provide meaningful benefit and may carry unnecessary risk.

Brain MRI: What It Can (and Cannot) Tell Us

Brain MRI is an essential part of the evaluation, but it rarely provides a single definitive answer. Distinct imaging patterns exist for ischemic brain disease, age-related atrophy, and hydrocephalus, yet these findings often coexist in older patients.

MRI may show:

• changes suggestive of chronic small vessel ischemia,
• features consistent with generalized brain atrophy,
• or ventricular enlargement compatible with hydrocephalus, with or without signs associated with elevated intracranial pressure.

Importantly, similar MRI appearances can reflect different underlying mechanisms, and ventricular enlargement alone does not establish the diagnosis. MRI findings must therefore be interpreted in combination with clinical presentation, cognitive profile, disease progression, and other diagnostic indicators to determine whether hydrocephalus plays a meaningful role in the patient’s symptoms.

Image: Brain MRI in elderly patients often shows cerebral atrophy combined with enlarged ventricles. Specialized evaluation is required to determine whether these enlarged ventricles represent active hydrocephalus or are simply enlarged due to brain atrophy (compensatory enlargement).

Incidental Ventriculomegaly on Brain MRI: When to Monitor and What to Track

Ventricular enlargement is sometimes discovered incidentally on MR brain imaging performed for unrelated reasons, before clear clinical symptoms of normal pressure hydrocephalus are present. In such cases, immediate intervention is usually not indicated, but structured clinical follow-up is important.

Patients should be monitored for early changes in gait, cognition, and urinary function. Subtle gait instability, slowed walking, difficulty with turns, reduced attention, executive dysfunction, or new urinary urgency may represent the earliest clinical signals of progression. In the absence of symptoms, clinical reassessment is typically reasonable at intervals of 6 to 12 months, or earlier if new neurological or functional complaints emerge. Repeat imaging is not routinely required unless clinical status changes.

Establishing a formal baseline assessment of gait and cognitive function can be particularly useful when ventricular enlargement is pronounced or when the clinical picture is borderline. Objective baseline measurements allow earlier detection of progression and support timely decision-making if symptoms begin to evolve.

Temporary CSF Reduction (Lumbar Tap Test): Indications, Procedure, and Interpretation

A temporary reduction of cerebrospinal fluid (CSF) volume (30-50 ml) via lumbar puncture is not intended as a general screening tool and should not be performed as a routine procedure. It is indicated only after a structured clinical evaluation suggests that hydrocephalus—normal pressure or chronic communicating—contributes meaningfully to the patient’s neurological deficits, rather than representing an incidental imaging finding.

When the Test Is Considered

A cerebrospinal fluid (CSF) tap test is considered only after potentially reversible or confounding factors have been addressed. This includes careful review and optimization of centrally acting medications, such as sedatives, antidepressants, and antipsychotics. It also includes exclusion of acute or subacute neurological or medical complications, for example chronic subdural hematoma, infection, or metabolic disturbances.

A documented baseline is then established through neurological examination and objective assessment of gait, balance, and cognitive function. Brain imaging, medical history, eye examination findings, prior neurological events, response to medication adjustments or trial therapies, and the tempo of symptom progression are considered together as part of this integrated evaluation.

The purpose of the tap test is not to confirm a diagnosis, but to assess whether symptoms show signs of physiological reversibility. No single finding is decisive on its own. Instead, the likelihood that hydrocephalus is meaningfully contributing to a patient’s symptoms depends on the combined interpretation of clinical findings, brain imaging, and functional assessment. A lack of improvement after a tap test does not rule out potential benefit from shunt surgery. Rather, a positive response to the test provides supportive evidence—alongside clinical and imaging features—that cerebrospinal fluid diversion may lead to symptom improvement.

How the Procedure Is Performed

The test consists of a controlled lumbar puncture, during which the opening pressure is measured at the start of the procedure to document whether intracranial pressure appears elevated, followed by the removal of approximately 30–50 mL of CSF under sterile conditions.

Before CSF removal, the following are documented:

• baseline gait performance, including walking speed over a 10-meter distance, step length, turning, and balance; video recording is particularly useful when the patient is unable to walk independently, as it allows objective comparison with post–tap test performance.
• baseline cognitive and attentional function (structured bedside or formal tests),
• baseline functional status as reported by patient and caregivers.

After CSF removal, the same parameters are reassessed, typically:

• within 2-4 hours, and
• again over the following 24–72 hours, depending on the clinical protocol.
• Improvements in gait are often detected early, while changes in cognitive function and urinary symptoms may appear later and are therefore monitored for up to 7 days.

Image: Performing a lumbar puncture for a CSF tap test, involving measuring initial ICP, and the evacuation of 30–50 mL of cerebrospinal fluid.

What Constitutes a Meaningful Response

Improvement after CSF removal is often subtle rather than dramatic and must be evaluated objectively.

A positive response may include:

• measurable improvement in gait initiation, speed, or stability,
• clearer attention, improved responsiveness, or reduced psychomotor slowing,
• improved ability to perform daily activities noted by caregivers.

Crucially, gait improvement following a tap test tends to be more immediate and robust than changes in cognition or urinary control. This discrepancy occurs for two main reasons: first, neurological recovery of cognitive function requires more time to manifest post-drainage; and second, while gait is directly linked to CSF dynamics, cognition and bladder control are often concurrently compromised by pre-existing vascular brain atrophy—a condition present in the majority of these elderly patients.

How Results Are Interpreted

Interpretation requires caution:

• Improvement supports—but does not guarantee—benefit from permanent CSF diversion.
• Absence of improvement does not automatically exclude benefit, particularly in patients with advanced disease, mixed pathology, or delayed response patterns.
• Responses may be influenced by placebo effects, medication adjustments, fatigue, or day-to-day variability, which is why objective comparison to baseline is essential.

The test therefore provides probabilistic guidance, not certainty. It helps estimate whether reducing CSF volume is likely to alleviate symptoms, but it does not replace clinical judgment.

Clinical Meaning of the Test

A favorable response suggests that hydrocephalus-related mechanisms are functionally relevant and that the patient may benefit from further consideration of CSF diversion strategies. Conversely, a negative or equivocal response highlights the need for caution and reinforces the importance of integrating all clinical, imaging, and functional data before proceeding.

What to Do If the Tap Test Is Inconclusive

If a single large-volume lumbar tap test does not result in clear clinical improvement, this does not rule out idiopathic normal pressure hydrocephalus. In such cases, additional diagnostic steps may be considered.

Repeating the tap test under standardized conditions can sometimes reveal subtle or delayed changes, particularly in gait. If the clinical response remains unclear, extended lumbar cerebrospinal fluid drainage is often the next step. This involves continuous CSF drainage through a lumbar catheter over several days, typically 2 to 3 days, during which the patient is encouraged to mobilize and walk under supervision. Repeated assessment of gait, balance, and functional performance during this period often provides stronger prognostic information than a single tap test.

In selected centers, a CSF infusion test may also be used to assess cerebrospinal fluid outflow resistance. However, because patients must remain supine during the procedure and functional improvement cannot be assessed, this test is not routinely used and rarely changes clinical decision-making.

When Surgical Treatment Is Considered

Surgical diversion of cerebrospinal fluid may be considered when:

• symptoms significantly impair function,
• hydrocephalus appears to contribute meaningfully,
• overall health permits intervention,
• expectations are realistic.

Outcomes vary widely. Improvement is most likely in gait, less predictable in bladder function, and often limited for cognition. Surgery is most beneficial in patients where clinical symptoms, imaging findings, and functional testing all point in the same direction — otherwise, the chance of improvement is significantly lower.

Why the Decision About Surgery Is Often Unclear

Uncertainty arises because:

• MRI findings are not self-explanatory,
• pressure measurements capture only a moment in time,
• symptom overlap with dementia is substantial,
• treatment benefits are probabilistic rather than guaranteed.

This complexity explains why answers to important questions may differ. The reasons are outlined below.

Why MRI Findings Alone Are Not Sufficient?

MRI often shows enlarged ventricles together with brain atrophy or vascular changes, but these findings can have different causes. Ventricular enlargement may reflect hydrocephalus, age-related atrophy, or both, and imaging alone cannot determine which process is actually responsible for the patient’s symptoms.

Why Symptoms Overlap Between Hydrocephalus And Dementia?

Gait disturbance, cognitive decline, and urinary problems can be caused by normal pressure hydrocephalus, vascular brain disease, or neurodegenerative dementia. Because these conditions frequently coexist, it is often unclear which one is the dominant driver of symptoms.

Why No Single Test Can Confirm The Diagnosis?

Tests such as the lumbar tap test or CSF drainage can suggest reversibility, but they are not definitive. A positive response increases the likelihood of benefit, while a negative result does not exclude potential improvement, making interpretation inherently uncertain.

Why Treatment Outcomes Are Not Predictable?

Even when hydrocephalus contributes to symptoms, outcomes after shunt surgery vary because most patients have mixed pathology. Improvement is usually most visible in gait, while cognitive and urinary changes are less predictable, depending on the degree of coexisting brain damage.

Why Do Some Specialists Recommend Surgery While Others Do Not?

Recommendations differ because the decision depends on how each specialist weighs the potential reversibility of symptoms against the risks of surgery. Some consider intervention justified when there is a reasonable chance that hydrocephalus contributes to symptoms, particularly when gait impairment is prominent and potentially reversible. Others recommend a more conservative approach when degenerative or vascular brain changes appear to dominate, or when the expected benefit is uncertain relative to the procedural risk.

Ventriculoperitoneal (VP) Shunt With Programmable Valve: What It Means in Practice

When permanent cerebrospinal fluid (CSF) diversion is considered, the most commonly used procedure is ventriculoperitoneal (VP) shunt placement. The operation involves creating a small opening in the skull to place a thin catheter into a brain ventricle. This catheter is connected to a valve system and a soft tube that runs under the skin, usually behind the ear and along the neck and chest, directing excess CSF into the abdominal cavity, where it is safely absorbed.

In some centers, lumboperitoneal (LP) shunts are frequently utilized, which divert cerebrospinal fluid from the lumbar subarachnoid space to the peritoneal cavity. Additionally, ventriculoatrial (VA) shunts are reserved for specific, selected cases where traditional drainage routes are not feasible.

Why a Programmable Valve Is Essential

In older patients with suspected normal pressure or chronic communicating hydrocephalus, programmable valves are strongly preferred. Programmable is preferred when available; in some settings fixed-pressure valves are used with acceptable outcomes when chosen carefully and monitored properly.

A programmable valve allows:

• non-invasive adjustment of CSF drainage pressure,
• gradual and individualized regulation of CSF outflow over time,
• avoidance of abrupt overdrainage, which can be harmful.

Rather than choosing a single fixed pressure at surgery, treatment becomes a stepwise process.

How Pressure Adjustment Works

After shunt implantation:

• the valve is initially set to a relatively higher opening pressure,
• the patient is observed clinically over days to weeks,
• pressure is then gradually lowered in controlled steps if symptoms persist and no complications occur.

Adjustments are performed externally, using a magnetic programming device placed over the scalp. No surgery, puncture, or anesthesia is required.

This gradual strategy allows the brain to adapt to changing CSF dynamics and helps identify the lowest effective pressure that provides benefit without causing harm.

What Is Monitored After Shunt Placement

Follow-up focuses on clinical function, not imaging alone.

Key parameters include:

• gait stability and walking confidence,
• balance and fall frequency,
• cognitive clarity and responsiveness,
• urinary control,
• overall functional independence.

Imaging may be used selectively to exclude complications, but clinical response is the primary guide for valve adjustment.

Expected Benefits and Realistic Outcomes

When hydrocephalus is a significant contributor to symptoms, clinical improvement after shunt surgery is common but variable. Reported improvement rates vary widely across studies and depend strongly on diagnostic criteria, patient selection, comorbidities, and follow-up protocols. Across published studies, improvement rates of approximately 40–80% within the first 3–6 months and 60–70% at 1–2 years have been reported in appropriately selected patients, with outcomes depending strongly on diagnostic criteria and patient selection. The degree of improvement varies across different clinical deficits:

• gait improvement is usually the earliest and most reliable response,
• cognitive changes, if present, are often modest and gradual,
• urinary symptoms may improve variably.

Improvement reflects reversal of hydrocephalus-related dysfunction, not treatment of underlying neurodegenerative disease. In carefully selected patients, shunt surgery can significantly improve walking and quality of life, but in others it may bring little benefit — which is why proper preoperative evaluation is critical.

Potential Complications (What Patients Should Know)

VP shunt surgery is a standard neurosurgical procedure, but it is not risk-free.

Possible complications include:

• overdrainage, which may cause headaches, dizziness, or subdural fluid collections,
• underdrainage, resulting in limited or absent symptom improvement,
• shunt malfunction or blockage,
• infection,
• abdominal complications (rare).

The use of a programmable valve significantly reduces the risk of long-term complications by allowing pressure correction without repeated surgery.

Why Experience Matters

Determining:

• when to implant a shunt,
• which valve to use,
• how quickly to adjust pressure,
• and how to interpret partial or delayed responses

requires substantial clinical experience. VP shunt treatment is not a single event but a dynamic, long-term management process tailored to each patient’s physiology and symptom profile.

Image: The illustration shows a ventriculoperitoneal (VP) shunt placed for hydrocephalus, which drains excess cerebrospinal fluid (CSF) into the abdominal cavity. The components of the shunt include a ventricular catheter, a programmable valve—designed to precisely regulate CSF drainage to prevent both under-drainage and over-drainage—and a distal catheter that routes the fluid from the valve into the abdomen.

Read about how hydrocephalus can be associated with the occurrence of spontaneous CSF leaks.

When an Expert Neurosurgical Second Opinion Is Valuable

A neurosurgical second opinion is most helpful when diagnostic findings are mixed, test results are inconclusive, or treatment decisions carry meaningful risk. In these situations, an experienced review can help determine whether hydrocephalus is a major driver of symptoms, clarify the role and limitations of further testing, and define realistic expectations regarding VP shunt surgery, valve adjustment, and long-term follow-up.

Frequently Asked Questions About Normal Pressure Hydrocephalus and Similar Conditions

Public awareness note: Public attention to normal pressure hydrocephalus increased in 2025 after musician Billy Joel publicly disclosed an NPH diagnosis. Celebrity cases can help families recognize that NPH is a real and often misunderstood condition, but diagnosis and treatment decisions should always depend on the patient’s own symptoms, MRI findings, neurological examination, response to CSF drainage testing, and overall medical condition.